Equity research analysts at Baird have $58 target price per share on InflaRx (NASDAQ:IFRX). Baird’s target price per share indicates a potential upside of 51.24% from the company’s last stock close price. The rating was revealed in a research report on 29 March.
Gain Capital Holdings Inc (GCAP) investors sentiment increased to 1.42 in Q4 2018. It’s up 0.37, from 1.05 in 2018Q3. The ratio has improved, as 47 investment professionals started new or increased equity positions, while 33 decreased and sold their positions in Gain Capital Holdings Inc. The investment professionals in our database now possess: 20.66 million shares, up from 19.76 million shares in 2018Q3. Also, the number of investment professionals holding Gain Capital Holdings Inc in top ten equity positions was flat from 2 to 2 for the same number . Sold All: 8 Reduced: 25 Increased: 29 New Position: 18.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” on February 27, 2019, also Seekingalpha.com with their article: “InflaRx down 14% – Seeking Alpha” published on November 19, 2018, Globenewswire.com published: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” published on January 03, 2019 as well as Globenewswire.com‘s news article titled: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” with publication date: February 06, 2019.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $995.74 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved in developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on April, 4. After $-0.31 actual earnings per share reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 41.94% negative EPS growth.
The stock decreased 2.12% or $0.83 during the last trading session, reaching $38.35. About 2,501 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 29, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs
GAIN Capital Holdings, Inc. provides trading services and solutions to retail, institutional, and futures service clients worldwide. The company has market cap of $235.16 million. The firm operates in three divisions: Retail, Institutional, and Futures. It has a 3.02 P/E ratio. It specializes in over-the-counter and exchange-traded markets.
Since January 1, 0001, it had 1 buy, and 2 sales for $253,540 activity.
Analysts await GAIN Capital Holdings, Inc. (NYSE:GCAP) to report earnings on April, 25. They expect $0.09 earnings per share, down 75.00% or $0.27 from last year’s $0.36 per share. GCAP’s profit will be $3.36M for 17.47 P/E if the $0.09 EPS becomes a reality. After $-0.11 actual earnings per share reported by GAIN Capital Holdings, Inc. for the previous quarter, Wall Street now forecasts -181.82% EPS growth.
Francisco Partners Management Lp holds 6.21% of its portfolio in GAIN Capital Holdings, Inc. for 186,435 shares. Signia Capital Management Llc owns 418,463 shares or 2.99% of their US portfolio. Moreover, Kestrel Investment Management Corp has 1.37% invested in the company for 442,350 shares. The New York-based Robotti Robert has invested 0.89% in the stock. Csat Investment Advisory L.P., a Michigan-based fund reported 91,637 shares.
The stock decreased 0.16% or $0.01 during the last trading session, reaching $6.29. About 2,861 shares traded. GAIN Capital Holdings, Inc. (GCAP) has risen 3.00% since March 29, 2018 and is uptrending. It has underperformed by 1.37% the S&P500. Some Historical GCAP News: 09/05/2018 – GAIN CAPITAL INSTITUTIONAL ECN VOLUME $ 279M, UP 21%; 05/04/2018 – GAIN CAPITAL – EXPANDED BITCOIN OFFERING ALLOWING CUSTOMERS TO TRADE BITCOIN DIRECTLY AGAINST EURO, BRITISH POUND & AUSTRALIAN DOLLAR; 05/04/2018 – GAIN CAPITAL EXPANDS CRYPTOCURRENCY OFFERING; 12/03/2018 – GAIN Capital Clarifies Impact of U.S. Tax Cuts and Jobs Act on Fourth Quarter and Full Year 2017 Results; 30/05/2018 – GAIN CAPITAL HOLDINGS INC GCAP.N – TO SELL GTX ECN BUSINESS TO DEUTSCHE BÖRSE GROUP’S FX UNIT, 360T FOR $100 MLN IN CASH; 30/05/2018 – PRESS RELEASE – GAIN CAPITAL TO SELL GTX ECN BUSINESS TO DEUTSCHE BöRSE GROUP’S FX UNIT, 360T; 08/03/2018 GAIN CAPITAL 4Q NET REV. $69.7M, EST. $72.8M; 27/03/2018 – GAIN Cap Responds to ESMA Statement; 09/05/2018 – GAIN Capital Announces Monthly Metrics for April 2018; 30/05/2018 – Deutsche Boerse to Buy GTX’s ECN Business From GAIN Capital for $100M
More notable recent GAIN Capital Holdings, Inc. (NYSE:GCAP) news were published by: Prnewswire.com which released: “GAIN Capital Announces Monthly Metrics for February 2019 – PRNewswire” on March 11, 2019, also Seekingalpha.com with their article: “GAIN Capital November – Seeking Alpha” published on December 10, 2018, Streetinsider.com published: “Gain Capital (GCAP) Commences Modified Dutch Auction Tender Offer to Purchase up to $50M of its Common Stock – StreetInsider.com” on October 09, 2018. More interesting news about GAIN Capital Holdings, Inc. (NYSE:GCAP) were released by: Globenewswire.com and their article: “Report: Developing Opportunities within General Electric, Arch Capital Group, China Petroleum & Chemical, Alexion Pharmaceuticals, GAIN Capital, and Sony â€” Future Expectations, Projections Moving into 2018 – GlobeNewswire” published on November 02, 2018 as well as Benzinga.com‘s news article titled: “Next Way To Play The Bitcoin Boom: Gain Capital (NYSE:GCAP) – Benzinga” with publication date: October 27, 2017.